MedTrace Logo

Optimal Treatment for Coronary Drug Eluting Stent In-stent Restenosis

NCT04862052 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2026-05-19

No results posted yet for this study

Summary

The aim of this open label, randomized study is to compare the safety and efficacy of three different methods to handle coronary drug eluting stent (DES) in-stent restenosis (ISR).

These are the:

* Magic Touch - sirolimus coated balloon
* Emperor - paclitaxel and dextran coated balloon
* Xience - chromium-cobalt everolimus eluting stent

Conditions

  • Coronary Stent Restenosis

Interventions

PROCEDURE

Intravascular management of prior implanted coronary drug eluting stent restenosis

Intravascular devices will be assessed for the management of prior implanted drug eluting stent restenosis management.

Sponsors & Collaborators

  • Semmelweis University Heart and Vascular Center

    lead OTHER

Principal Investigators

  • István F Édes, MD PhD · Semmelweis University Heart and Vascular Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-26
Primary Completion
2025-01-30
Completion
2025-01-30

Countries

  • Hungary

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04862052 on ClinicalTrials.gov